Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

In a meta-analysis of four geographically diverse observational studies, a higher intake of any type of chili pepper was associated with a lower rate of death from CV disease, cancer, or all causes.

Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ...

US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on ...

TORONTO (AP) — U.S. President Donald Trump will arrive Sunday for a Group of Seven summit in a country he has suggested should be annexed and as he wages a ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...